Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK
oleh: M Hoyle, L Crathorne, R Garside, C Hyde
| Format: | Article |
|---|---|
| Diterbitkan: | NIHR Journals Library 2011-05-01 |
Deskripsi
No description available for this item.